TP53 and B-cell chronic lymphocytic leukemia: We demonstrated that only a minority of CLL patients achieved long-term progression-free survival (PFS), reliably identifiable by combining TP53 disruption status, IGHV mutation analysis, telomere length (TL) and CD49d expression.